Drug Interaction Study of Simvastatin and Dabigatran

Inclusion Criteria: * Healthy male subjects between the ages of 19 and 50 years * Subjects with body mass index (BMI) between 18.5 and 29.9 kg/m2 and weight more than 50 kg * Subjects who agree with performing contraception during the study * Subjects who agreed with written informed consent Exclusion Criteria * Subjects who have a current or prior history of cardiovascular, respiratory, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, skin, psychiatric, or neurological diseases that is clinically significant * Subjects who have clinically significant allergic history or allergy to simvastatin, dabigatran, or other components of drug * Creatinine clearance is below 60 ml/min * Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) is more than 2-fold of upper limit or normal range * Subjects who have clinically significant bleeding * Subjects at risk of bleeding * Subjects who took drugs which significantly interact with simvastatin or dabigatran prior to dosing * Whole blood donation within 60 days prior to dosing, or apheresis donation within 20 days prior to dosing * Participated in a previous clinical trial within 90 days prior to dosing * Subjects with a history of alcohol abuse * Subjects who are determined by investigator's decision as unsuitable for clinical trial participation